Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside.
Novavax, Inc.'s (NASDAQ: NVAX) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate.
Bristol-Myers Squibb Co (NYSE: BMY) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis.
The week also saw a medical technology and two biotechs debuting on the Wall Street.
Here are the key catalysts for the unfolding week.
Conferences
BTIG Virtual Biotechnology Conference: Aug. 10-11
Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12
PDUFA Dates
The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC) for EM-100, an investigational therapy for allergic conjunctivitis. The company had licensed this preservative-free ophthalmic solution from Eton Pharmaceuticals Inc (NASDAQ: ETON). (Monday)
The agency is also due to announce its decision on Fennec Pharmaceuticals Inc's (NASDAQ: FENC) NDA for Pedmark, which is being evaluated as a treatment option for chemotherapy-induced ototoxicity. (Monday)
FDA's decision on label expansion for Roche Holdings AG's Basel ADR Common Stock (OTC: RHHBY) Xolair for the treatment of nasal polyps could come Tuesday, based on 10 months from the submission of the sBLA.
Adcom Calendar
FDA' Oncology Drug Advisory Committee will discuss Thursday Mesoblast limited's (NASDAQ: MESO) BLA for remestemcel-L for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Earnings
Monday
-
Rubius Therapeutics Inc (NASDAQ: RUBY) (before the market open)
-
Reata Pharmaceuticals Inc (NASDAQ: RETA) (before the market open)
-
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) (before the market open)
-
Paratek Pharmaceuticals Inc (NASDAQ: PRTK) (before the market open)
-
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open)
-
TG Therapeutics Inc common stock (NASDAQ: TGTX) (before the market open)
-
Recro Pharma Inc (NASDAQ: REPH) (before the market open)
-
Radius Health Inc (NASDAQ: RDUS) (before the market open)
-
Voyager Therapeutics Inc (NASDAQ: VYGR) (before the market open)
-
Chimerix Inc (NASDAQ: CMRX) (before the market open)
-
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (before the market open)
-
SAGE Therapeutics Inc (NASDAQ: SAGE) (before the market open)
-
Neos Therapeutics Inc (NASDAQ: NEOS) (before the market open)
-
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open)
-
Protalix BioTherapeutics, Inc. (NASDAQ: PLX) (before the market open)
-
Intra-Cellular Therapies Inc (NASDAQ: ITCI) (before the market open)
-
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) (before the market open)
-
Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open)
-
Amicus Therapeutics, Inc. (NASDAQ: FOLD) (before the market open)
-
Apyx Medical Corp (NASDAQ: APYX) (before the market open)
-
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (before the market open)
-
Akebia Therapeutics Inc (NASDAQ: AKBA) (before the market open)
-
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the market close)
-
Athersys Inc (NASDAQ: ATHX) (after the market close)
-
Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the market close)
-
Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the market close)
-
Clearside Biomedical Inc (NASDAQ: CLSD) (after the market close)
-
Pulse Biosciences Inc (NASDAQ: PLSE) (after the market close)
-
Calithera Biosciences Inc (NASDAQ: CALA) (after the market close)
-
Castle Biosciences Inc (NASDAQ: CSTL) (after the market close)
-
Matinas BioPharma Holdings Inc (NYSE: MTNB) (after the market close)
-
Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (after the market close)
-
CASI Pharmaceuticals Inc (NASDAQ: CASI) (after the market close)
-
Celcuity Inc (NASDAQ: CELC) (after the market close)
-
CorMedix Inc. (NYSE: CRMD) (after the market close)
-
Integra Lifesciences Holdings Corp (NASDAQ: IART) (after the market close)
-
Cara Therapeutics Inc (NASDAQ: CARA) (after the market close)
-
Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the market close)
-
Precigen Inc NASDAQ: (PGEN) (after the market close)
-
Rockwell Medical Inc (NASDAQ: RMTI) (after the market close)
-
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (after the market close)
-
ICU Medical Inc (NASDAQ: ICUI) (after the market close)
-
Plus Therapeutics Inc (NASDAQ: PSTV) (after the market close)
-
Liquidia Technologies Inc (NASDAQ: LQDA) (after the market close)
-
Novavax
-
Wave Life Sciences Ltd (NASDAQ: WVE) (after the market close)
-
Urogen Pharma Ltd (NASDAQ: URGN) (after the market close)
-
CymaBay Therapeutics Inc (NASDAQ: CBAY) (after the market close)
-
ChemoCentryx Inc (NASDAQ: CCXI) (after the market close)
-
Chiasma Inc (NASDAQ: CHMA) (after the market close)
-
Organogenesis Holdings Inc (NASDAQ: ORGO) (after the market close)
-
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the market close)
-
Esperion Therapeutics Inc (NASDAQ: ESPR) (after the market close)
-
Evolus Inc (NASDAQ: EOLS) (after the market close)